Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a total revenue of 24.972 billion yuan for 2025, representing a year-on-year increase of 19.53%. The net profit attributable to shareholders was 12.35 billion yuan, up 18.91% year-on-year, with an EPS of 1.35 yuan [7] - The brokerage business saw significant growth, with revenues increasing by 43.8% year-on-year, contributing 35.6% to total revenue. The company also experienced a 40% increase in margin financing and securities lending balance [7] - The investment banking segment generated 1.03 billion yuan in revenue, a 20% increase year-on-year, with a total underwriting scale of 171.5 billion yuan [7] - Asset management revenue rose by 21.7% year-on-year, with the management scale of public funds increasing significantly [7] - The company is expected to see net profits of 13.6 billion yuan in 2026 and 14.6 billion yuan in 2027, reflecting growth rates of 10% and 7% respectively [7] Financial Summary - Total revenue forecast for 2024 is 20.891 billion yuan, increasing to 30.773 billion yuan by 2028, with a compound annual growth rate (CAGR) of approximately 4.14% [1] - The net profit attributable to shareholders is projected to grow from 10.386 billion yuan in 2024 to 15.494 billion yuan in 2028, with a CAGR of about 6% [1] - The company's P/E ratio is expected to decrease from 13.55 in 2024 to 8.59 in 2028, indicating an improving valuation over time [1]

Investment Rating - The investment rating for the company is "Accumulate" [5] Core Views - The company is expected to maintain strong revenue and profit growth in 2025, with total revenue projected at 62.05 billion yuan, representing a year-on-year increase of 67.89%, and a net profit of 17.94 billion yuan, up 89.82% year-on-year [10] - The company has a strong long-cycle operational capability, with existing products expected to generate stable revenue in 2026, supported by new releases such as "Zhang Jian Chuan Shuo" and "Wen Jian Chang Sheng" in new regions, as well as the launch of "Lost Castle 2" [2][10] - The company is projected to achieve earnings per share (EPS) of 27.16 yuan in 2026, with a target price set at 543.20 yuan based on a 20x dynamic PE ratio [10] Financial Summary - Total revenue is forecasted to grow from 62.05 billion yuan in 2025 to 80.62 billion yuan by 2028, with a compound annual growth rate (CAGR) of approximately 9.3% [4] - Net profit attributable to shareholders is expected to increase from 17.94 billion yuan in 2025 to 25.54 billion yuan in 2028, reflecting a CAGR of about 14.5% [4] - The company maintains a high dividend payout ratio, with an expected cash dividend of 14.06 billion yuan in 2025, translating to a dividend rate of 78.41% [10] Product Performance - Key products such as "Zhang Jian Chuan Shuo" and "Dao You Lai Wa Bao" are expected to drive revenue and profit growth, with "Zhang Jian Chuan Shuo" projected to generate 25 billion yuan in revenue [10] - The company’s older product "Wen Dao Mobile Game" is anticipated to stabilize its revenue due to a long-term operational strategy, with a slight decline of 6.55% in 2025 [10] - The new product "Jiu Mu Zhi Ye" is expected to launch in December 2025, with initial revenue projections of over 200 million yuan within three months [10]

| 报告原因：有业绩公布需要点评 | | --- | | 增持（维持） | | 市场数据： | 2026 年 03 月 27 日 | | --- | --- | | 收盘价（元） | 6.89 | | 一年内最高/最低（元） | 9.45/6.38 | | 市净率 | 2.8 | | 股息率%（分红/股价） | - | | 流通 A 股市值（百万元） | 80,187 | | 上证指数/深证成指 | 3,913.72/13,760.37 | | 注："股息率"以最近一年已公布分红计算 | | 上 市 公 司 公 司 研 究 / 公 司 点 评 证 券 研 究 报 告 王凯婕 A0230525110001 wangkj@swsresearch.com 投资要点： | 基础数据: | 2025 年 12 月 31 日 | | --- | --- | | 每股净资产（元） | 2.44 | | 资产负债率% | 88.56 | | 总股本/流通 A 股（百万） | 17,448/11,638 | | 流通 B 股/H 股（百万） | -/4,563 | 一年内股价与大盘对比走势： -20% -10% 0% 10% ...

证券研究报告·公司点评报告·化学制药 | [Table_EPS] 盈利预测与估值 | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 11,812 | 12,020 | 12,483 | 13,863 | 15,449 | | 同比（%） | (4.97) | 1.76 | 3.85 | 11.06 | 11.44 | | 归母净利润（百万元） | 2,061 | 2,023 | 2,055 | 2,338 | 2,777 | | 同比（%） | 5.50 | (1.84) | 1.59 | 13.73 | 18.80 | | EPS-最新摊薄（元/股） | 2.32 | 2.28 | 2.31 | 2.63 | 3.13 | | P/E（现价&最新摊薄） | 14.68 | 14.95 | 14.72 | 12.94 | 10.89 | [Table_Tag] [Table_Summary] 投资要点 2026 年 03 月 28 日 证券分析师 朱国广 丽珠集团（000 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong performance relative to the market [7]. Core Insights - The company reported a revenue of 2.144 billion yuan for 2025, representing a year-on-year growth of 35.7%, and a net profit of 434 million yuan, which is a 91.1% increase year-on-year [4][6]. - The company is benefiting from high demand in the PCB industry, with significant revenue contributions from precision tools and grinding materials [7]. - The company plans to invest 5 billion yuan in building a smart manufacturing headquarters, which is expected to enhance production capacity and support revenue growth [7]. Financial Data and Profit Forecast - The projected total revenue for 2026 is 3.455 billion yuan, with a year-on-year growth rate of 61.2% [6]. - The net profit forecast for 2026 is 839 million yuan, reflecting a year-on-year growth of 93.5% [6]. - The company’s gross margin is expected to improve to 44.8% by 2026, up from 42.3% in 2025 [6]. - The earnings per share (EPS) is projected to reach 2.05 yuan in 2026, indicating strong profitability growth [6].

Investment Rating - The report maintains a rating of "Buy" for the company with a target price of 11.91 CNY per share [6][12]. Core Insights - The company's performance in 2025 aligns with the pre-announcement, driven by rapid growth in investment and brokerage businesses. As a large brokerage firm with a strong wealth management label, it is expected to benefit from the trend of residents moving their deposits [2][12]. - The company achieved a net profit of 5.634 billion CNY in 2025, representing a year-on-year increase of 68%. Adjusted revenue (operating income minus other business costs) was 15.35 billion CNY, up 26% year-on-year [12][13]. - The company is projected to see net profits of 6.583 billion CNY, 7.371 billion CNY, and 8.091 billion CNY for 2026, 2027, and 2028 respectively, with year-on-year growth rates of 17%, 12%, and 10% [12][13]. Financial Summary - **Revenue and Profit Forecasts**: - Operating revenue for 2025 is forecasted at 15.358 billion CNY, down 20% from 2024, with a recovery expected in subsequent years [4][13]. - Net profit attributable to shareholders is projected to grow from 5.634 billion CNY in 2025 to 8.091 billion CNY by 2028 [4][12]. - **Earnings Per Share (EPS)**: - EPS is expected to increase from 0.66 CNY in 2025 to 0.95 CNY in 2028 [4][12]. - **Return on Equity (ROE)**: - ROE is projected to rise from 6.8% in 2025 to 8.3% in 2028 [4][12]. - **Market Capitalization and Valuation**: - The company's market capitalization is approximately 77.404 billion CNY, with a current price of 9.11 CNY per share [7][12]. - The price-to-earnings (P/E) ratio is expected to decrease from 13.74 in 2025 to 9.57 in 2028 [4][12]. Business Segments - **Revenue Breakdown**: - In 2025, revenue from investment, brokerage, investment banking, and asset management was 6.99 billion CNY, 2.92 billion CNY, 1.50 billion CNY, and 1.36 billion CNY respectively, with year-on-year growth rates of 40%, 16%, 29%, and 1% [12][13]. - **Asset Management**: - The asset management segment contributed 9.3 billion CNY in profit, accounting for 16.5% of total profits, with a year-on-year increase of 5.7% [12][13]. - **Investment Strategy**: - The company is focusing on expanding its equity investments and maintaining a stable leverage ratio, with an operating leverage of 4.11x at the end of the period [12][13].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 88.20 CNY, based on a projected average PE of 36 times for comparable companies in 2026 [3][6]. Core Insights - The company is expected to see profit growth driven by its seating and overseas business expansion, with projected net profits for 2026-2028 at 1.25 billion, 1.58 billion, and 1.98 billion CNY respectively, reflecting significant growth rates [2][3]. - The company aims to enhance its global footprint, with plans for subsidiaries in Malaysia and investments in factories in Mexico and Slovakia, indicating a strong commitment to international market development [10]. Financial Performance Summary - Revenue projections for 2024A to 2028E are as follows: 13.26 billion CNY (2024A), 15.52 billion CNY (2025A), 19.62 billion CNY (2026E), 24.27 billion CNY (2027E), and 29.29 billion CNY (2028E), with growth rates of 25.5%, 17.0%, 26.4%, 23.7%, and 20.7% respectively [5]. - The company's gross profit margin is expected to stabilize around 19.1% to 19.4% from 2026E to 2028E, while net profit margins are projected to improve from 6.4% in 2026E to 6.7% in 2028E [5][10]. - The company’s earnings per share (EPS) are forecasted to increase from 2.45 CNY in 2026E to 3.87 CNY in 2028E, indicating a positive trend in profitability [5][10]. Business Growth Drivers - The seating and robotics segments are identified as key growth areas, with expectations for the seating business to turn profitable as new models are launched and production scales up [10]. - The robotics business is also progressing, with strategic partnerships aimed at enhancing product development and manufacturing capabilities, positioning the company as a significant player in this sector [10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company's 2025 annual report shows revenue of 12.02 billion yuan, a year-on-year increase of 1.76%, and a net profit attributable to shareholders of 2.02 billion yuan, a decrease of 1.84% [8] - The report highlights strong performance in the biopharmaceutical and traditional Chinese medicine segments, with overseas revenue growth of 12% [8] - The company is accelerating its innovation pipeline, with several new drugs expected to launch soon, including those for psoriasis and diabetes [8] - The long-term outlook remains positive due to diversified strategic positioning and ongoing international market expansion [8] Financial Summary - Total revenue forecast for 2024 is 11.81 billion yuan, with a projected increase to 15.45 billion yuan by 2028 [1] - Net profit is expected to fluctuate slightly, with a forecast of 2.06 billion yuan in 2024 and 2.78 billion yuan by 2028 [1] - The company's earnings per share (EPS) is projected to be 2.32 yuan in 2024, increasing to 3.13 yuan by 2028 [1] - The price-to-earnings (P/E) ratio is expected to decrease from 14.68 in 2024 to 10.89 by 2028, indicating a potentially undervalued stock [1]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company reported a total operating revenue of 82.53 billion yuan in 2025, a year-on-year decrease of 9.3%, while the net profit attributable to shareholders was 8.11 billion yuan, an increase of 5.4% year-on-year [8] - The company has demonstrated cost control through technological innovation and logistics management, resulting in a decrease of 11.12% in comprehensive costs for cement and clinker products [8] - The company is actively expanding its industrial chain, with successful projects in both domestic and overseas markets, including the completion of the acquisition of the Xinjiang Yaobai project and the operation of the Cambodia project [8] - The company plans to reduce capital expenditures while increasing its dividend payout ratio, which reached 55.3% in 2025, up by 6.6 percentage points year-on-year [8] - The report anticipates a gradual improvement in industry conditions in 2026, supported by self-discipline within the industry and potential policy impacts [8] Financial Summary - The company forecasts total operating revenue of 84.91 billion yuan for 2026, with a projected net profit of 9.14 billion yuan, reflecting a year-on-year growth of 12.66% [1] - The earnings per share (EPS) is expected to increase from 1.53 yuan in 2025 to 1.72 yuan in 2026 [1] - The price-to-earnings (P/E) ratio is projected to decrease from 15.05 in 2025 to 13.36 in 2026, indicating a potential valuation recovery [1]

Investment Rating - The report maintains a "Recommendation" rating for Ruifeng Bank, with a target price of 7.07 yuan [2][7]. Core Insights - Ruifeng Bank's core revenue capacity has strengthened, with net interest income and other income growth accelerating. However, non-interest income has declined significantly, impacting overall revenue [7]. - The bank's net profit attributable to shareholders increased by 2.30% year-on-year, but the growth rate has slowed due to pressure on small and micro enterprises' repayment capabilities [7]. - The bank's non-performing loan (NPL) ratio rose slightly to 0.99%, while the provision coverage ratio decreased to 327% [7]. Financial Performance Summary - For the year 2025, Ruifeng Bank achieved total operating revenue of 4.408 billion yuan, a year-on-year increase of 0.53% [8]. - The net profit attributable to shareholders for 2025 was 1.966 billion yuan, with a growth rate of 2.30% [8]. - The bank's total assets are projected to grow steadily, with expected revenue growth rates of 4.3%, 7.2%, and 10.4% for 2026, 2027, and 2028 respectively [7][8]. Asset Quality and Risk Indicators - The NPL ratio is expected to gradually improve, projected to decrease to 0.93% by 2028 [10]. - The provision coverage ratio is forecasted to remain stable, with a slight increase to 332.17% by 2028 [10]. - The bank's loan growth is anticipated to be steady, with total loans expected to reach 194.842 billion yuan by 2028 [9].